孟鲁司特联合普米克令舒对肺炎支原体肺炎患儿气道高反应性的影响

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (33 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore and analyze on the effect of Montelukast combined with Pulmicort on airway hyper-reactivity in children with Mycoplasma pneumoniae pneumonia.Methods From March 2016 to July 2017,a total of 98 cases of children with Mycoplasma pneumoniae pneumonia treated in our hospital were selected as the research objects.The random number table method was used to divide them into reference group and combination group,with 49 cases in each group.The reference group was treated with routine antibiotic treatment and the combination group was treated with routine antibiotics+Montelukast+Pulmicort treatment.The related indexes were compared between the two groups.Results After treatment,the mutation rate of peak expiratory flow(PEF),serum tumor necrosis factor-α (TNF-α)and interleukin-6 (IL-6)levels in the two groups were significantly lower than before treatment,while the mutation rate of PEF,TNF-α and IL-6 in the combination group were lower than those in the reference group,the differences were statistically significant(P＜0.05).The distribution of comprehensive efficacy and the total effective rate in the combination group were significantly different from those in the reference group (P＜0.05).Conclusion On the basis of conventional antibiotics treatment in children with Mycoplasma pneumoniae pneumonia,the Montelukast combined with Pulmicort can improve airway hyper-reactivity,significantly control the inflammatory response and enhance the comprehensive curative effect.

Key words： Montelukast Pulmicort Mycoplasma pneumoniae pneumonia Airway hyper-reactivity

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Hong
	REN Yan-ni
	DENG Guo-xiong

Cite this article:

ZHANG Hong,REN Yan-ni,DENG Guo-xiong. Effect of Montelukast combined with Pulmicort on airway hyper-reactivity in children with Mycoplasma pneumoniae pneumonia[J]. 中国当代医药, 2018, 25(11): 124-126.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I11/124

[7]	蔡惠东，潘剑蓉.阿奇霉素联合孟鲁司特钠治疗小儿肺炎支原体肺炎的疗效评价[J].检验医学与临床，2017，14（17）：2590-2592.
[1]	王红连.儿童肺炎支原体肺炎发病状况与疾病负担的研究[J].临床肺科杂志，2015，20（7）：1266-1269.
[2]	刘锋，曾邦智，王甜甜.普米克令舒辅助治疗对支原体肺炎患儿炎性因子免疫功能及肺功能的影响[J].山西医药杂志，2017，46（13）：1614-1617.
[3]	胡亚美.诸福棠实用儿科学，上册[M].人民卫生出版社，2002：102-103.
[4]	张建梅，周金芳，王敏，等.阿奇霉素、孟鲁司特钠联合普米克令舒治疗对支原体肺炎儿童炎症程度、肺功能的影响[J].海南医学院学报，2016，22（18）：2171-2173.
[6]	朱冰，陈维宪，李敏妍.阿奇霉素联合孟鲁司特钠治疗小儿肺炎支原体肺炎的疗效及其对血清C反应蛋白水平的影响[J].临床和实验医学杂志，2015，14（1）：41-43.
[5]	Yoon IA，Hong KB，Lee HJ，et al.Radiologic findings as a determinant and no effect of macrolide resistance on clinical course of Mycoplasma pneumoniae pneumonia[J].BMC Infect Dis，2017，17（1）：402.
[8]	李远西.普米克令舒雾化联合孟鲁司特钠治疗对支气管哮喘患儿肺功能及炎症状态的影响[J].西北国防医学杂志，2017，38（2）：121-124.
[9]	于水莲，曲书强.肺炎支原体肺炎患儿血清及支气管肺泡灌洗液IL-6、IL-10水平的变化[J].中国妇幼保健，2017，32（16）：3800-3802.
[10]	肖红亮.孟鲁司特联合阿奇霉素治疗儿童支原体肺炎的效果观察[J].中国妇幼保健，2017，32（12）：2664-2666.
[11]	王英，雷蓓蓓.布地奈德联合孟鲁司特钠治疗肺炎支原体肺炎的疗效及其对肺功能和炎性细胞因子的影响[J].儿科药学杂志，2017，23（5）：23-25.
[12]	康钰，郭利明.布地奈德混悬液联合阿奇霉素序贯治疗幼儿支原体肺炎[J].西部医学，2015，27（12）：1842-1844.
[13]	李鸿鸣.痰热清联合阿奇霉素治疗小儿肺炎支原体肺炎疗效观察[J].中国当代医药，2011，18（9）：55.
[14]	李琳霞.痰热清联合阿奇霉素治疗小儿肺炎支原体肺炎的疗效观察[J].中国当代医药，2012，19（11）：71-72.
[15]	李彦夫.阿奇霉素序贯疗法治疗小儿肺炎支原体肺炎的临床疗效研究[J].中国当代医药，2012，19（7）：74-75.